The ADepT-PD trial (nortriptyline)
This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. Here, Dr Simon Stott talks about the sub-study being funded by Cure…
The AND-PD Trial
This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…
The AZA-PD Trial (azathioprine)
Dr Williams-Gray’s team at the University of Cambridge’s Centre for Parkinson-Plus are conducting a clinical trial of azathioprine (AZA-PD), a medication already used to treat inflammation by dampening down the immune system’s response, with the aim of slowing brain cell damage and slowing the progression of Parkinson’s….
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and…
The PROSEEK trial of KO706
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor KO706 in people with early Parkinson’s.